DNA Biomed (Israel) Top Management
| DNA Stock | ILS 94.70 3.00 3.27% |
DNA Biomed employs about 11 people. The company is managed by 3 executives with a total tenure of roughly 9 years, averaging almost 3.0 years of service per executive, having 3.67 employees per reported executive. Analysis of DNA Biomed's management performance can provide insight into the company performance.
| Tony Klein President Vice President - Finance |
DNA |
DNA Biomed Management Team Effectiveness
The company has return on total asset (ROA) of (0.0375) % which means that it has lost $0.0375 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2509) %, meaning that it generated substantial loss on money invested by shareholders. DNA Biomed's management efficiency ratios could be used to measure how well DNA Biomed manages its routine affairs as well as how well it operates its assets and liabilities.DNA Biomed Workforce Comparison
DNA Biomed Solns is one of the top stocks in number of employees category among related companies. The total workforce of Information Technology industry is currently estimated at about 12,415. DNA Biomed adds roughly 11.0 in number of employees claiming only tiny portion of equities under Information Technology industry.
DNA Biomed Solns Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. DNA Biomed Solns Price Series Summation is a cross summation of DNA Biomed price series and its benchmark/peer.
DNA Biomed Notable Stakeholders
A DNA Biomed stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as DNA Biomed often face trade-offs trying to please all of them. DNA Biomed's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting DNA Biomed's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Tony Klein | Vice President - Finance | Profile | |
| Michael Gaft | Chief Scientist | Profile | |
| Zvika LTC | VP Programs | Profile |
About DNA Biomed Management Performance
The success or failure of an entity such as DNA Biomed Solns often depends on how effective the management is. DNA Biomed management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of DNA management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the DNA management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
D.N.A Biomedical Solutions Ltd. develops and commercializes laser spectrometry-based trace detection systems in Israel. D.N.A Biomedical Solutions Ltd. was founded in 2004 and is based in Ramat Gan, Israel. D N operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange.
The data published in DNA Biomed's official financial statements usually reflect DNA Biomed's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of DNA Biomed Solns. For example, before you start analyzing numbers published by DNA accountants, it's critical to develop an understanding of what DNA Biomed's liquidity, profitability, and earnings quality are in the context of the Electronic Equipment, Instruments & Components space in which it operates.
Please note, the presentation of DNA Biomed's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, DNA Biomed's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in DNA Biomed's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of DNA Biomed Solns. Please utilize our Beneish M Score to check the likelihood of DNA Biomed's management manipulating its earnings.
DNA Biomed Workforce Analysis
Traditionally, organizations such as DNA Biomed use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare DNA Biomed within its industry.DNA Biomed Manpower Efficiency
Return on DNA Biomed Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Income Per Employee | 1.7M | |
| Net Income Per Executive | 6.1M | |
| Working Capital Per Employee | 1.6M | |
| Working Capital Per Executive | 6M |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DNA Biomed Solns. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. Note that the DNA Biomed Solns information on this page should be used as a complementary analysis to other DNA Biomed's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Complementary Tools for DNA Stock analysis
When running DNA Biomed's price analysis, check to measure DNA Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DNA Biomed is operating at the current time. Most of DNA Biomed's value examination focuses on studying past and present price action to predict the probability of DNA Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DNA Biomed's price. Additionally, you may evaluate how the addition of DNA Biomed to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |